Bangladesh based Healthcare Pharmaceuticals Ltd. (HPL) and Eli Lilly & Company announced the launch of CYRAMZA™ (ramucirumab injection, 10 mg/mL solution) in Bangladesh. Cyramza™, is an anti-cancer medicine that is approved as a single agent and/or in combination with other agents for cancers arising from stomach, lungs, liver or large bowel; that have spread to distant parts of the body, said a press release.
Speaking about the benefits to patients, Luca Visini, MD, Eli Lilly and Company India said, “Cancer impacts the lives of many people every year. We are pleased to bring to Bangladesh an option for the first-line treatment of people with metastatic non-small cell lung cancer (NSCLC) and second line treatment for people living with the burden of gastric cancer. We believe this will help us in moving several steps ahead in our collective goal to make lung and gastric cancer a less formidable challenge and a condition that can be managed.”
CYRAMZA™ is for use in cancers that are usually advanced or have spread despite other treatments. For most cancers it is used in combination with other medicines.
CYRAMZA™ is an anti-cancer medicine indicated to treat adult patients with gastric cancer(cancer of the stomach) or cancer of the area where the esophagus enters the stomach (known as gastro-esophageal junction adenocarcinoma); colorectal cancer (cancer of the large bowel that is advanced or metastatic cancers); non-small cell lung cancer (NSCLC) without actionable mutation or in non-small cell lung cancer driven by mutations (changes) in proteins called epidermal growth factor receptors(EGFRs); hepatocellular carcinoma (a type of liver cancer) in patients with a high blood level of a protein called alpha fetoprotein (AFP).
CYRAMZA™ plus erlotinib is the first and only US FDA-approved anti-VEGFR/EGFR TKI combination therapy for EGFR-mutated metastatic NSCLC.
